{"entity":{"id":"constellation-pharmaceuticals","kind":"company","name":"Constellation Pharmaceuticals","aka":["Constellation Pharmaceuticals, Inc."],"tldr":"Constellation Pharmaceuticals developed medicines for cancer that change which genes are switched on in cancer cells. MorphoSys bought it in 2021, and its drugs pelabresib and CPI-0209 (now tulmimetostat) went with it.","summary":"Constellation Pharmaceuticals was a clinical-stage company developing therapeutics that selectively modulate gene expression for patients with cancer (Third Rock Ventures). MorphoSys AG completed a cash tender offer at $34.00 a share on 15 July 2021, with a total equity value of about $1.7 billion, and Constellation became an indirect wholly owned subsidiary of MorphoSys. The MorphoSys release names Constellation's clinical-stage assets as pelabresib (CPI-0610) and CPI-0209, and also mentions two earlier programmes. Its common stock had traded on Nasdaq as CNST. MorphoSys is itself now part of Novartis.","asOf":"2026-11-04","links":[{"label":"MorphoSys completes acquisition (SEC 6-K exhibit, 15 July 2021)","url":"https://www.sec.gov/Archives/edgar/data/1340243/000119312521215759/d193747dex991.htm"},{"label":"Third Rock Ventures portfolio entry","url":"https://www.thirdrockventures.com/portfolio/constellation"}],"tags":[],"related":[],"cancers":[],"sections":["epigenetics"],"technologies":[],"targets":[],"drugs":["pelabresib","tulmimetostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated in the sources read (2008 is Third Rock's year of investment).","HQ from the SEC EDGAR business address (215 First Street, Cambridge, MA).","Existing OnCo drug records that came from Constellation: pelabresib and tulmimetostat (CPI-0209); they can link here.","Targets for pelabresib and CPI-0209 are not stated in the release read, so none set here."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","stage":"acquired","investors":["third-rock-ventures"],"funding":[],"acquiredBy":"morphosys"},"route":"/companies/constellation-pharmaceuticals/","neighbours":{"section":[{"id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","route":"/fronts/epigenetics/"}],"drug":[{"id":"pelabresib","kind":"drug","name":"Pelabresib","route":"/drugs/pelabresib/"},{"id":"tulmimetostat","kind":"drug","name":"Tulmimetostat","route":"/drugs/tulmimetostat/"}],"company":[{"id":"morphosys","kind":"company","name":"MorphoSys (Novartis)","route":"/companies/morphosys/"},{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/"}]}}